© 2009

cGMP: Generators, Effectors and Therapeutic Implications

  • Harald H. H. W. Schmidt
  • Franz Hofmann
  • Johannes-Peter Stasch

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 191)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Basic Generators and Effectors

    1. Alexander Y. Kots, Emil Martin, Iraida G. Sharina, Ferid Murad
      Pages 1-14
    2. Emily R. Derbyshire, Michael A. Marletta
      Pages 17-31
    3. Evanthia Mergia, Doris Koesling, Andreas Friebe
      Pages 33-46
    4. Martin Biel, Stylianos Michalakis
      Pages 111-136
    5. Franz Hofmann, Dominik Bernhard, Robert Lukowski, Pascal Weinmeister
      Pages 137-162
    6. Jens Schlossmann, Matthias Desch
      Pages 163-193
    7. Viacheslav O. Nikolaev, Martin J. Lohse
      Pages 229-243
  3. Pharmacology of cGMP

    1. Ian L. Megson, Mark R. Miller
      Pages 247-276
    2. Johannes-Peter Stasch, Adrian J. Hobbs
      Pages 277-308
    3. Harald H. H. W. Schmidt, Peter M. Schmidt, Johannes-Peter Stasch
      Pages 309-339
    4. Lincoln R. Potter, Andrea R. Yoder, Darcy R. Flora, Laura K. Antos, Deborah M. Dickey
      Pages 341-366
    5. Sharron H. Francis, Jackie D. Corbin, Erwin Bischoff
      Pages 367-408
    6. Christopher J. Reaume, Marla B. Sokolowski
      Pages 423-443
  4. Clinical Applications

    1. Barbara Kemp-Harper, Harald H. H. W. Schmidt
      Pages 447-467

About this book


After the discovery of endogenous NO formation in the late '80s and the 1998 Nobel Prize in Physiology or Medicine, many researchers and physicians again became interested in the NO/sGC interaction and cGMP-dependent signaling. This book is an enthusiastic celebration of cyclic guanosine monophosphate (cGMP) and amply illustrates the importance of this field of science to patients and the way in which the field has evolved. It is exclusively devoted to this exciting and important signaling molecule, addressing all recent advances in understanding guanylate cyclase regulation, NO/sGC interactions, cGMP effector mechanisms and their pathophysiological and pharmacological implications. Particular attention will also be given to clinical applications of the novel cGMP-elevating drugs which are on the horizon, thus spanning the continuum from basic science to clinic.


Regulation blood cell cGMP guanylyl cyclase phosphodiesterase physiology protein kinase G

Editors and affiliations

  • Harald H. H. W. Schmidt
    • 1
  • Franz Hofmann
    • 2
  • Johannes-Peter Stasch
    • 3
  1. 1.Dept. PharmacologyMonash UniversityClaytonAustralia
  2. 2.Inst. Pharmakologie und ToxikologieTU MünchenMünchenGermany
  3. 3.Bayer Schering Pharma AG Cardiology ResearchPharma Research CenterWuppertalGermany

Bibliographic information

Industry Sectors
Chemical Manufacturing
Health & Hospitals
Consumer Packaged Goods